MTSET-氯化物 | 210167-37-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 中文名称: MTSET-氯化物
• 英文名称: [2-(trimethylammonium)ethyl] methanethiosulfonate
• 英文别名: MTSET；Methanethiosulfonate ethyl trimethylammonium；Trimethyl-(2-methylsulfonylsulfanylethyl)azanium bromide；trimethyl(2-methylsulfonylsulfanylethyl)azanium
• CAS: 210167-37-6
• 化学式: C₆H₁₆NO₂S₂
• 分子量: 198.331
• InChiKey: VRGHSYHERKHVHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  67.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  MTSET-氯化物 、 serine protease subtilisin Bacillus lentus 166 serine -> cysteine mutant 生成 serine protease subtilisin Bacillus lentus 166 serine -> cysteine mutant with modified thiol side chain by introducing S-(CH2)2-NMe3(1+) group
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Delivery of a substance to a pre-determined site
  申请人：Friesen Heinz Edward Robert

  公开号：US20050272677A1

  公开（公告）日：2005-12-08

  The invention is directed to delivery vehicles for delivering a substance of interest to a predetermined site. The delivery vehicle includes a substance and means for inducing availability of at least one compartment of the delivery vehicle toward the exterior, thus, allowing access of the substance to the exterior of the delivery vehicle at the predetermined site. The invention is further directed to uses of the delivery vehicle and methods for preparing the delivery vehicle.

  本发明涉及用于将所需物质传递至预定地点的传递车辆。该传递车辆包括物质和诱导至少一个传递车辆隔室向外部可用的手段，从而允许在预定地点将物质访问到传递车辆的外部。本发明还涉及传递车辆的用途和制备传递车辆的方法。
• Delivery of small hydrophilic molecules packaged into lipid vesicles
  申请人：——

  公开号：US20030118636A1

  公开（公告）日：2003-06-26

  Methods and compositions for the generation of vehicles for delivering small molecules are disclosed. In one aspect, lipid vesicles having a proteinaceous channel and small molecules are generated. The proteinaceous channel and/or the lipid vesicle are formulated such that the small molecule is released in the vicinity of or near a target cell. The target cell may be located in vitro or in vivo.

  本发明揭示了用于生成用于传递小分子的载体的方法和组合物。在一个方面，生成具有蛋白质通道和小分子的脂质囊泡。蛋白质通道和/或脂质囊泡的配方使小分子在靠近或接近目标细胞的位置释放。目标细胞可以位于体外或体内。
• POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF
  申请人：THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICE

  公开号：US20160009644A1

  公开（公告）日：2016-01-14

  Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.

  本文揭示了双芳基甲硫基乙酰胺和双芳基甲硫基乙胺作为单胺转运体抑制剂的用途。这些化合物是通过它们各自的转运体DAT、SERT和NET对多巴胺（DA）、5-羟色胺（5-HT）和/或去甲肾上腺素（NE）的再摄取具有强效和/或选择性抑制作用。还揭示了利用这些化合物引发促醒、认知或注意力增强效应以及治疗物质使用障碍、注意缺陷（多动）障碍、抑郁障碍、双相障碍或其他神经精神障碍、睡眠障碍或认知障碍的方法。
• Compositions useful in treating brain-related diseases or disorders and methods using same
  申请人：DREXEL UNIVERSITY

  公开号：US10287290B2

  公开（公告）日：2019-05-14

  The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

  本发明提供了用于治疗或预防脑相关疾病或紊乱的化合物。本发明进一步提供了一种治疗或预防患者脑相关疾病或紊乱的方法，包括向患者施用包含至少一种本发明化合物的药物组合物。本发明进一步提供了一种调节单胺转运体活性的方法。
• Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
  申请人：THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

  公开号：US10590074B2

  公开（公告）日：2020-03-17

  Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.

  本文公开了可用作单胺转运体抑制剂的双芳基甲硫基乙酰胺和双芳基甲硫基乙胺。这些化合物是多巴胺（DA）、5-羟色胺（5-HT）和/或去甲肾上腺素（NE）通过各自的转运体 DAT、SERT 和 NET 再摄取的强效和/或选择性抑制剂。此外，还公开了利用这些化合物激发促进觉醒或认知或注意力增强效应以及治疗药物使用障碍、注意力缺陷（多动）症、抑郁症、双相情感障碍或其他神经精神疾病睡眠障碍或认知障碍的方法。